Carboxyimamidate, a low-molecular-weight polyelectrolyte with antitumor properties and low toxicity
- PMID: 7131485
- DOI: 10.1021/jm00351a011
Carboxyimamidate, a low-molecular-weight polyelectrolyte with antitumor properties and low toxicity
Abstract
A new polyelectrolyte was synthesized and evaluated for antitumor activity. The product is a derivative of ethylene/maleic anhydride copolymer of low molecular weight (Mn approximately equal to 1100). The anhydride groups were first converted to the half-amide, half-ammonium salt by reaction with ammonia. A percentage (14-25 wt %) of these groups was further converted to the imide by heating. The product, carboxyimamidate (Carbethimer, N-137) inhibited the growth of a number of solid tumors in vivo. Sensitive tumor models included Lewis lung carcinoma, Madison 109 lung carcinoma, M5076 ovarian tumor, colon carcinoma 26, B16 melanoma, and P815 mastocytoma. Activity was dose related between nontoxic dose levels of 300 and 2000 mg/kg ip.
Similar articles
-
Relationship of molecular weight to antiviral and antitumor activities and toxic effects of maleic anhydride-divinyl ether (MVE) polyanions.Cancer Treat Rep. 1978 Nov;62(11):1797-803. Cancer Treat Rep. 1978. PMID: 103618
-
Antitumor activity of an ionic titanocene tetrachloroferrate derivative against some solid experimental tumors.Arzneimittelforschung. 1989 Apr;39(4):488-90. Arzneimittelforschung. 1989. PMID: 2751735
-
Divinyl ether-maleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity.Nature. 1973 Nov 16;246(5429):160-2. doi: 10.1038/246160a0. Nature. 1973. PMID: 4586109 No abstract available.
-
[Antitumor activity of polyanion and its application for drug delivery system of antitumor drugs].Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):542-7. Gan To Kagaku Ryoho. 1990. PMID: 2138872 Review. Japanese.
-
Future direction of synthetic polyanions (pyran copolymer).Cancer Treat Rep. 1978 Nov;62(11):1853-6. Cancer Treat Rep. 1978. PMID: 365328 Review.
Cited by
-
Phase II trial of carbetimer in metastatic melanoma.Invest New Drugs. 1993 May-Aug;11(2-3):231-3. doi: 10.1007/BF00874162. Invest New Drugs. 1993. PMID: 8262738 Clinical Trial.
-
Phase I trial of the polyelectrolyte carbetimer administered i.v. once every four weeks.Invest New Drugs. 1988 Sep;6(3):189-94. doi: 10.1007/BF00175396. Invest New Drugs. 1988. PMID: 3192384
-
Phase II study of carbetimer in non-small cell lung cancer.Invest New Drugs. 1990 Nov;8(4):385-6. doi: 10.1007/BF00198596. Invest New Drugs. 1990. PMID: 1964676 Clinical Trial. No abstract available.
-
Phase I trial of a 5-day course of carbetimer.Invest New Drugs. 1990;8 Suppl 1:S41-9. doi: 10.1007/BF00171983. Invest New Drugs. 1990. PMID: 2380016
-
Activity of Carbetimer in a human tumor cloning system.Invest New Drugs. 1984;2(1):55-8. doi: 10.1007/BF00173787. Invest New Drugs. 1984. PMID: 6469499
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources